首页 / 院系成果 / 成果详情页

LDA-SVM-Based EGFR Mutation Model for NSCLC Brain Metastases An Observational Study 期刊论文

编号：

27ecb8b9-914a-4d9e-abf5-fc76f357af67
作者：

Hu, Nan#^[1]Wang, Ge#^[1]Wu, YuHao^[2];Chen, ShiFeng^[3];Liu, GuoDong^[4];Chen, Chuan^[1];Wang, Dong^[1];He, ZhongShi^[2];Yang, XueQin^[1];He, Yong^[5];Xiao, HuaLiang^[6];Huang, DingDe^[7];Xiong, KunLin^[8];Wu, Yan^[1];Huang, Ming^[9];Yang, ZhenZhou*^[1]
语种：

英文
期刊：

MEDICINE ISSN：0025-7974 2015 年 94 卷 5 期 ; FEB
收录：
摘要：

Epidermal growth factor receptor (EGFR) activating mutations are a predictor of tyrosine kinase inhibitor effectiveness in the treatment of non-small-cell lung cancer (NSCLC). The objective of this study is to build a model for predicting the EGFR mutation status of brain metastasis in patients with NSCLC.
Observation and model set-up.
This study was conducted between January 2003 and December 2011 in 6 medical centers in Southwest China.
The study included 31 NSCLC patients with brain metastases.
Eligibility requirements were histological proof of NSCLC, as well as sufficient quantity of paraffin-embedded lung and brain metastases specimens for EGFR mutation detection. The linear discriminant analysis (LDA) method was used for analyzing the dimensional reduction of clinical features, and a support vector machine (SVM) algorithm was employed to generate an EGFR mutation model for NSCLC brain metastases. Training-testing-validation (3 : 1 : 1) processes were applied to find the best fit in 12 patients (validation test set) with NSCLC and brain metastases treated with a tyrosine kinase inhibitor and whole-brain radiotherapy.
Primary and secondary outcome measures: EGFR mutation analysis in patients with NSCLC and brain metastases and the development of a LDA-SVM-based EGFR mutation model for NSCLC brain metastases patients.
EGFR mutation discordance between the primary lung tumor and brain metastases was found in 5 patients. Using LDA, 13 clinical features were transformed into 9 characteristics, and 3 were selected as primary vectors. The EGFR mutation model constructed with SVM algorithms had an accuracy, sensitivity, and specificity for determining the mutation status of brain metastases of 0.879, 0.886, and 0.875, respectively. Furthermore, the replicability of our model was confirmed by testing 100 random combinations of input values.
The LDA-SVM-based model developed in this study could predict the EGFR status of brain metastases in this small cohort of patients with NSCLC. Further studies with larger cohorts should be carried out to validate our findings in the clinical setting.
推荐引用方式
GB/T 7714：

Hu Nan,Wang Ge,Wu Yu-Hao, et al. LDA-SVM-Based EGFR Mutation Model for NSCLC Brain Metastases An Observational Study [J].MEDICINE,2015,94(5).
APA：

Hu Nan,Wang Ge,Wu Yu-Hao,Chen Shi-Feng,&Yang Zhen-Zhou.(2015).LDA-SVM-Based EGFR Mutation Model for NSCLC Brain Metastases An Observational Study .MEDICINE,94(5).
MLA：

Hu Nan, et al. "LDA-SVM-Based EGFR Mutation Model for NSCLC Brain Metastases An Observational Study" .MEDICINE 94,5(2015).
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：72  下载次数：0

分享到：

浏览次数：72

下载次数：0

打印次数：0